Table 6: Prevalence of TPOAb and TgAb in RA patients.

Author publication date Location Study population Number of Cases Diagnostic Frequency Prevalence % criteria of RA TPOAb TgAb TPOAb TgAb Africa  Assal et al. 2009 [73] Egypt F: 66.6% A: 26.8 30 ACR 1987 2 9 6.0 30.0  El-Sherif et al. 2004 [74] Egypt N/A 20 N/A N/A N/A 5.0 30.0  Mousa et al. 2012 [57] Egypt F: 80% A: 36.3 217 ACR 1987 22 13 10.1 6.0 America              Cárdenas et al. 2012* Colombia F: 81.3% A: 51.92 125–135** ACR 1987 51 26 37.8 20.8  Rivero et al. 1974 [75] Argentina N/A 50 N/A N/A 10 N/A 20.0  Innocencio et al. 2004  [76] Brazil N/A 25 ACR 1987 8 32.00  Gonçalves et al. 2009 [77] Brazil F: 86% A: 50 ± 10 72 ACR 1987 11 9 15.3 12.5 Asia                  Porkodi et al. 2004 [78] India N/A N/A N/A 21 13 2.8 1.8  Nakamura et al. 2008 [79] Japan F: 82.76% A: 61 ± 14 29 N/A 9 9 31.0 31.0 Europe  Hijmans et al. 1961 [23] Europe# N/A 86 ARA 1959 9 10.4  Atzeni et al. 2008 [80] Italy F: 81% A: 47 ± 16 70 ACR 1987 26 16 37.0 23.0  Ruggeri et al. 2002 [81]≠  Italy    N/A  N/A   N/A  N/A  N/A 1975–1982: 0 1990–1992: 12 1998-1999: 26  Genth et al. 1978 [82] Germany N/A 105 N/A 15 7 14.3 6.7  Andonopoulos et al. 1996 [83] Greece N/A 101 N/A N/A N/A 12.9 N/A  Raterman and Nurmohamed  2012 [84] NL N/A N/A ACR 1987 N/A N/A 15 N/A  Magnus et al. 1995 [85] Norway N/A 100 N/A N/A §  Przygodzka and  Filipowicz-Sosnowska 2009 [70] Poland F: 100% A: 56 ± 13 100 ACR 1987 15 12 15.0 12.0  Buchanan 1965 [86] Scotland F: 100% N/A N/A N/A N/A N/A 24.4  Yavasoglu et al. 2009 [87] Turkey F: 82% 82 ARA 1959 13 10 15.9 12.3  Silman et al. 1989 [88] UK N/A N/A N/A N/A N/A males: 5 females: 15 males: 5 females: 11 Middle East                   Al-Awadhi et al. 2008  [89] Kuwait F: 79.1% A: 38.3 177 ACR 1987 12 6 6.7 3.4

N/A: Not available; F: Proportion of females; A: Age at time of assessment (standard deviation); NL: The Netherlands; UK: United Kingdom; USA: United States of America. *Current series. **See text for details. #Location not stated. Collaboration among UK and NL. §Compared to the prevalence in the normal population, patients with rheumatoid arthritis have a higher prevalence of both antibodies. ≠Prevalence assessed in three time points. Only valid for thyroid hormone antibodies (THAb).